Triple combination therapy or triple therapy (inhibiting BRAF, MEK and PD1/PDL1 axis) showed significantly longer progression-free survival compared to BRAF + MEK combination therapies (HR = 0.76; 95% CI 0.64–0.9), but similar objective and complete response rates in BRAF-mutated melanoma. Here, MAP2K7 is linked to melanoma.